


IN THE CLAIMS:

Please amend the claims as follows:

1. (Currently amended) A conjugate of hydrophilic polymer-multicarboxyl oligopeptide and drug molecule of the following formula:



wherein:

P is a water-soluble hydrophilic polymer selected from the group consisting of polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyacrylmorpholine and copolymers thereof;

m is an integer from 2-12 inclusive;

j is an integer from 1-6 inclusive;

R_i is a group selected from the group consisting of H, C₁₋₁₂ alkyl, substituted aryl, aralkyl, heteroalkyl and substituted alkyl;


X is a linking group selected from the group consisting of (CH₂)_i, (CH₂)_iOCO, (CH₂)_iNHCO and (CH₂)_iCO, and wherein i is an integer from 0-10, inclusive;

Z is a linking group selected from O and NH; and

TA is a drug molecule selected from the group consisting of organic acids, terpenoids, phenylpropanoid phenols, steroids, alkaloids, etoposide, and esters thereof.

Application Serial No.: 10/506,524

2. (Canceled)
3. (Currently amended) The conjugate of claim [[2]]1, wherein the water soluble hydrophilic polymer is polyethylene glycol.
4. (Previously presented) The conjugate of claim 3, wherein the molecular weight of polyethylene glycol is from 300 to 60,000.
5. (Canceled)
6. (Previously presented) The conjugate of claim 1, wherein a free hydroxyl on the hydrophilic polymer can be substituted by C₁₋₁₂ alkoxy, cycloalkoxy or aroxy.
7. (Currently amended) The conjugate of claim 1, wherein a free hydroxyl on the hydrophilic polymer is substituted by the following formula:



wherein:

m is an integer from 2-12 inclusive;

j is an integer from 1-6 inclusive;

Application Serial No.: 10/506,524

R_i is a group selected from the group consisting of H, C₁₋₁₂ alkyl, substituted aryl, aralkyl, heteroalkyl and substituted alkyl;

X is a linking group selected from the group consisting of (CH₂)_i, (CH₂)_iOCO, (CH₂)_iNHCO and (CH₂)_iCO, and wherein i is an integer from 0-10, inclusive;

Z is a linking group selected from O and NH; and

TA is a drug molecule selected from the group consisting of organic acids, terpenoids, phenylpropanoid phenols, steroids, alkaloids, etoposide, and esters thereof.

8. (Previously presented) The conjugate of claim 1, wherein target molecule can be carried in the hydrophilic polymer to perform targeted delivery of the conjugate.

9. (Previously presented) The conjugate of claim 8, wherein the target molecule is an antibody.

10. (Canceled)


11. (Canceled)

12. (Withdrawn) The conjugate of claim 1[[1]], wherein the active ingredient is cinobufagin, clycyrrhetic acid or scopoletin.

13. (Currently amended) The conjugate of claim 1[[0]], wherein the drug molecule TA is an antitumor agent.

14. (Previously presented) The conjugate of claim 13, wherein the antitumor agent is selected from the group consisting of paclitaxel, camptothecin, hydroxycamptothecin, etoposide and esters thereof.

15. (Previously presented) A conjugate of methoxypolyethylene glycol-glutamic acid oligopeptide and drug molecule having the following formula:



wherein:

n is an integer from 10-1200;

m is an integer from 2-12;

X is a linking group selected from the group consisting of $(\text{CH}_2)_i$, $(\text{CH}_2)_i\text{OCO}$, $(\text{CH}_2)_i\text{NHCO}$ and $(\text{CH}_2)_i\text{CO}$, and wherein i is an integer from 0-10 inclusive;

Z is a linking group selected from O and NH; and

PT is a drug molecule selected from the group consisting of paclitaxel, camptothecin, cinobufagin, clycyrrhetic acid, scopoletin and esters thereof.

16. (Previously presented) A composition comprising a conjugate according to claim 1 and a pharmaceutically acceptable carrier or excipient.

17. (Canceled)

18. (Previously presented) The composition of claim 16, wherein the composition is formulated into a form selected from the group consisting of a tablet, a suppository, a pill, a soft gelatin capsule, a hard gelatin capsule, a powder, a solution, a

Application Serial No.: 10/506,524

suspension, and an aerosol.

19. (Canceled)

20. (Previously presented) A composition comprising a conjugate according to claim 15 and a pharmaceutically acceptable carrier or excipient.

21. (Canceled)

22. (Previously presented) The composition of claim 20, wherein the composition is formulated into a form selected from the group consisting of a tablet, a suppository, a pill, a soft gelatin capsule, a hard gelatin capsule, a powder, a solution, a suspension, and an aerosol.